These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 33499241)

  • 1. Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs.
    Mashraqi MM; Chaturvedi N; Alam Q; Alshamrani S; Bahnass MM; Ahmad K; Alqosaibi AI; Alnamshan MM; Ahmad SS; Beg MMA; Mishra A; Shaikh S; Rizvi SMD
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights from the molecular docking analysis of SGLT2 and FIMH to combat uropathogenicity.
    Abdulaal WH; Bakhrebah MA; Nassar MS; Almazni IA; Almutairi WA; Natto ZS; Khattab AK
    Bioinformation; 2022; 18(11):1044-1049. PubMed ID: 37693079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface display of uropathogenic Escherichia coli FimH in Lactococcus lactis: In vitro characterization of recombinant bacteria and its protectivity in animal model.
    Derakhshandeh S; Shahrokhi N; Khalaj V; Habibi M; Moazzezy N; Asadi Karam MR; Bouzari S
    Microb Pathog; 2020 Apr; 141():103974. PubMed ID: 31926238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Bouzari S
    APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target Selectivity of FimH Antagonists.
    Scharenberg M; Schwardt O; Rabbani S; Ernst B
    J Med Chem; 2012 Nov; 55(22):9810-6. PubMed ID: 23088608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d-Mannose Treatment neither Affects Uropathogenic
    Scribano D; Sarshar M; Prezioso C; Lucarelli M; Angeloni A; Zagaglia C; Palamara AT; Ambrosi C
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31941080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiadhesive natural products against uropathogenic E. coli: What can we learn from cranberry extract?
    Scharf B; Schmidt TJ; Rabbani S; Stork C; Dobrindt U; Sendker J; Ernst B; Hensel A
    J Ethnopharmacol; 2020 Jul; 257():112889. PubMed ID: 32311481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.
    Asadi Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
    Vaccine; 2013 Feb; 31(8):1210-6. PubMed ID: 23306365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidating novel antibacterial compounds from the NPASS database against the FimH lectin domain for the treatment of urinary tract infections: an in-silico study.
    Al-Zrkani MK; Abdulkareem RA; Al-Fahad D; Al Shouber M; Nasr AMS; Al-Khdhairawi A
    J Biomol Struct Dyn; 2023 Jun; 41(9):3914-3925. PubMed ID: 35403563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosylation changes as important factors for the susceptibility to urinary tract infection.
    Taganna J; de Boer AR; Wuhrer M; Bouckaert J
    Biochem Soc Trans; 2011 Jan; 39(1):349-54. PubMed ID: 21265802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding.
    Chen SL; Hung CS; Pinkner JS; Walker JN; Cusumano CK; Li Z; Bouckaert J; Gordon JI; Hultgren SJ
    Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22439-44. PubMed ID: 20018753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional characterization of the FimH adhesin of uropathogenic Escherichia coli and its novel applications.
    Foroogh N; Rezvan M; Ahmad K; Mahmood S
    Microb Pathog; 2021 Dec; 161(Pt B):105288. PubMed ID: 34780972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposed dual antagonist approach for the prevention and treatment of urinary tract infections caused by uropathogenic Escherichia coli.
    Ribić R; Meštrović T; Neuberg M; Kozina G
    Med Hypotheses; 2019 Mar; 124():17-20. PubMed ID: 30798908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
    Rizvi SM; Shakil S; Biswas D; Shakil S; Shaikh S; Bagga P; Kamal MA
    CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):447-51. PubMed ID: 24059302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation.
    Klein T; Abgottspon D; Wittwer M; Rabbani S; Herold J; Jiang X; Kleeb S; Lüthi C; Scharenberg M; Bezençon J; Gubler E; Pang L; Smiesko M; Cutting B; Schwardt O; Ernst B
    J Med Chem; 2010 Dec; 53(24):8627-41. PubMed ID: 21105658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection.
    Kalas V; Hibbing ME; Maddirala AR; Chugani R; Pinkner JS; Mydock-McGrane LK; Conover MS; Janetka JW; Hultgren SJ
    Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2819-E2828. PubMed ID: 29507247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation.
    Schwartz DJ; Kalas V; Pinkner JS; Chen SL; Spaulding CN; Dodson KW; Hultgren SJ
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15530-7. PubMed ID: 24003161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection.
    Thankavel K; Madison B; Ikeda T; Malaviya R; Shah AH; Arumugam PM; Abraham SN
    J Clin Invest; 1997 Sep; 100(5):1123-36. PubMed ID: 9276729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and development of FimH lectin domain for rising immune response after injection by uropathogenic E. coli.
    Zandi M; Fallah Mehrabadi J; Mahdavi M; Irani S
    Hum Antibodies; 2020; 28(2):169-178. PubMed ID: 32116244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.